Synopsis of recent research by authors named "Yutaro Kotobuki"
- Yutaro Kotobuki's recent research primarily focuses on the cost-effectiveness and therapeutic benefits of empagliflozin, a sodium-glucose co-transporter 2 inhibitor, in treating heart failure and related cardiovascular conditions, particularly among Japanese patients with varying ejection fractions.
- His studies utilize Markov cohort models to assess the economic implications and clinical efficiency of empagliflozin, positioning it against standard care in heart failure management, which highlights its potential for improving patient outcomes in a cost-effective manner.
- Additionally, Kotobuki has explored the experiences and needs of individuals with insulin resistance syndrome and lipoatrophic diabetes, aiming to better understand the treatment burdens and support required for these rare conditions in Japan.
